Cardiol Therapeutics Inc.
Cardiol Therapeutics is a clinical-stage life sciences company dedicated to developing high-impact therapies for heart disease, focusing on anti-inflammatory and anti-fibrotic treatments. Their mission is to discover novel therapeutic approaches that improve outcomes for patients suffering from underserved heart diseases, including pericarditis, myocarditis, and heart failure. They are engaged in clinical trials and collaborate with international research centers to advance their innovative solutions.
Industries
Nr. of Employees
small (1-50)
Cardiol Therapeutics Inc.
1000-161 Bay Street, Toronto, ON M5J 2S8, Canada
Products
Pharmaceutically manufactured cannabidiol oral solution (clinical-stage drug candidate)
An orally administered cannabidiol formulation developed as a small-molecule therapeutic candidate intended to modulate inflammation and fibrosis in cardiac diseases; advanced into Phase II and Phase III clinical trials for pericarditis and myocarditis.
Subcutaneous small-molecule anti-inflammatory/anti-fibrotic formulation (development candidate)
A subcutaneously administered small-molecule formulation under development for heart failure indications, intended to address anti-inflammatory and anti-fibrotic mechanisms.
Pharmaceutically manufactured cannabidiol oral solution (clinical-stage drug candidate)
An orally administered cannabidiol formulation developed as a small-molecule therapeutic candidate intended to modulate inflammation and fibrosis in cardiac diseases; advanced into Phase II and Phase III clinical trials for pericarditis and myocarditis.
Subcutaneous small-molecule anti-inflammatory/anti-fibrotic formulation (development candidate)
A subcutaneously administered small-molecule formulation under development for heart failure indications, intended to address anti-inflammatory and anti-fibrotic mechanisms.
Services
Engagement with academic centers, clinical investigators and industry partners to advance therapeutic candidates through preclinical and clinical development.
Collaborative engagement with nonprofit patient organizations to support patient education, awareness campaigns and community resources related to pericardial disease.
Engagement with academic centers, clinical investigators and industry partners to advance therapeutic candidates through preclinical and clinical development.
Collaborative engagement with nonprofit patient organizations to support patient education, awareness campaigns and community resources related to pericardial disease.
Expertise Areas
- Clinical trial management
- Cardiovascular inflammation and fibrosis research
- Cannabinoid-related pharmacology for therapeutic development
- Regulatory strategy and submissions (FDA/IND, orphan designation)
Key Technologies
- Cannabinoid pharmacology
- Inflammasome pathway modulation
- Oral liquid formulation technologies
- Subcutaneous drug formulation technologies
News & Updates
A detailed patient story highlighting the challenges faced by a woman living with recurrent pericarditis, emphasizing the importance of research, community support, and perseverance.
A detailed patient story highlighting the challenges faced by a woman living with recurrent pericarditis, emphasizing the importance of research, community support, and perseverance.